Guggenheim Upgrades Audentes Therapeutics (BOLD) to Buy
Tweet
Share
E-mail
Get Alerts BOLD Hot Sheet
Price: $2.92 -0.68%
Rating Summary:
3 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 20 | New: 18
Rating Summary:
3 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 20 | New: 18
Join SI Premium – FREE
Guggenheim analyst Whitney Ijem upgraded Audentes Therapeutics (NASDAQ: BOLD) from Neutral to Buy with a price target of $35.00.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $24.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Deutsche Bank Upgrades Bytes Technology Group PLC (BYIT:LN) to Buy
- HSBC Upgrades Bank of East Asia (23:HK) (BKEAY) to Buy
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
